BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 28205231)

  • 21. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
    Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
    Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
    Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
    Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer.
    Gao Y; Zhu Y; Yuan Z
    Int J Med Sci; 2016; 13(12):902-913. PubMed ID: 27994495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
    Pietrasz D; Wang-Renault S; Taieb J; Dahan L; Postel M; Durand-Labrunie J; Le Malicot K; Mulot C; Rinaldi Y; Phelip JM; Doat S; Blons H; de Reynies A; Bachet JB; Taly V; Laurent-Puig P
    Br J Cancer; 2022 Feb; 126(3):440-448. PubMed ID: 34811505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
    Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
    Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
    Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B
    Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer.
    Motobayashi H; Kitahata Y; Okada KI; Miyazawa M; Ueno M; Hayami S; Miyamoto A; Shimizu A; Sato M; Yoshimura T; Nakamura Y; Takemoto N; Nakai T; Hyo T; Matsumoto K; Yamaue H; Kawai M
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):35. PubMed ID: 38277079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection.
    Lim DH; Yoon H; Kim KP; Ryoo BY; Lee SS; Park DH; Song TJ; Hwang DW; Lee JH; Song KB; Kim SC; Hong SM; Hyung J; Yoo C
    Cancer Res Treat; 2023 Oct; 55(4):1313-1320. PubMed ID: 37139665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.
    Thomsen CB; Hansen TF; Andersen RF; Lindebjerg J; Jensen LH; Jakobsen A
    J Exp Clin Cancer Res; 2018 Mar; 37(1):55. PubMed ID: 29530101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.
    Uesato Y; Sasahira N; Ozaka M; Sasaki T; Takatsuki M; Zembutsu H
    PLoS One; 2020; 15(7):e0235623. PubMed ID: 32614932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.
    Fang Z; Meng Q; Zhang B; Shi S; Liu J; Liang C; Hua J; Yu X; Xu J; Wang W
    Aging (Albany NY); 2020 Dec; 13(2):2031-2048. PubMed ID: 33318293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.
    Chen S; Zhao J; Cui L; Liu Y
    Clin Transl Oncol; 2017 Mar; 19(3):332-340. PubMed ID: 27468867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
    Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
    Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
    Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
    Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical application of circulating tumor DNA in metastatic cancers.
    Raei N; Safaralizadeh R; Latifi-Navid S
    Expert Rev Mol Diagn; 2023; 23(12):1209-1220. PubMed ID: 37797209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Emergent Circulating Tumor DNA
    Kim TW; Peeters M; Thomas A; Gibbs P; Hool K; Zhang J; Ang AL; Bach BA; Price T
    Clin Cancer Res; 2018 Nov; 24(22):5602-5609. PubMed ID: 29898991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.